Industry

Novo licenses Hengrui’s preclinical obesity drug candidate for up to $2.6 billion

Novo will pay Hengrui $300 million upfront for ex-China rights to HRS-1596, with milestone payments that could bring the deal to $2.6 billion.

Reported by 3 outlets Wednesday, September 30, 2026

Orange prescription bottles on a table
Photo: Public domain

Fierce Biotech reported Novo will pay $300 million upfront, with potential milestone payments that could bring the deal’s total value to $2.6 billion.

Hengrui designed the GLP-1/GIP dual receptor agonist for once-weekly oral dosing. Novo said it aims to suppress appetite, stimulate insulin secretion and improve insulin sensitivity, for potential use in obesity, Type 2 diabetes and other metabolic diseases.

Fierce Biotech described HRS-1596 as preclinical and said regulators in China cleared it to enter phase 1 trials. BioPharma Dive reported that the drug has not been tested in humans and was described in a statement as “Phase 1 ready.”

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.